Siddharth Patel, ESC 2022: P2Y12 inhibition with ticagrelor in patients with higher lipoprotein A, the PEGASUS-TIMI 54 trial insights
With insights from the PEGASUS-TIMI 54 study, it was assessed whether patients with higher lipoprotein A treated with ticagrelor, a P2Y12 inhibitor, have a greater reduction in cardiovascular risk. In this touchCARDIO interview, we speak with Dr Siddharth Patel (Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA) to discuss the role of lipoprotein A in atherogenesis and the findings of his study presented at ESC 2022.
The abstract entitled ‘Lipoprotein(a), cardiovascular events, and benefit of P2Y12 inhibition: insights from the PEGASUS-TIMI 54 trial’ was presented at the European Society of Cardiology (ESC) Congress 2022, 26 – 29 August 2022.
- What is the role of anti-platelet therapy in chronic secondary prevention of atherothrombotic events in patients who have experienced a heart attack? (0:18)
- What is known about the role of lipoprotein A in atherogenesis? (1:24)
- What was the rationale for and design of the PEGASUS-TIMI 54 study? (2:18)
- What were the findings of the study? (3:06)
- On the basis of these findings, what are your recommendations for clinical practice? (4:02)
Disclosures: Siddharth Patel has received grant or research support from National Heart, Lung and Blood Institute (T32HL007604).
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Danielle Crosby.
Filmed as a highlight of ESC 2022
Access more content on Cardiovascular Risk here
Share this Video
Related Videos In Cardiovascular Disease
John Forrest, ACC 2023: Evolut low risk trial, transcatheter versus surgical aortic valve replacement in patients at low surgical risk
The Evolut low risk trial aimed to compare transcatheter versus surgical aortic valve replacement in patients who were at low risk for surgery. In this touchCARDIO interview, we speak with Dr John Forrest (Yale New Haven Hospital, Yale University, New Haven, CT, USA) to discuss the eligibility criteria, the key findings and the outlook for […]
John Forrest, ACC 2023: The treatment paradigm for patients with aortic stenosis
The treatment paradigm for aortic stenosis has developed dramatically in the past decade. In this touchCARDIO interview, we speak with Dr John Forrest (Yale New Haven Hospital, Yale University, New Haven, CT, USA) to outline and discuss the developments. Dr Forrest presented an abstract entitled ‘Transcatheter Versus Surgical Aortic Valve Replacement In Aortic Stenosis Patients […]
Steven Nissen, ACC 2023: Lipid-lowering therapies – current and future options
Many lipid-lowering therapies exist, such as statins to manage and reduce lipid levels. While statins are the most commonly used medication, some patients may need additional interventions to lower their LDL cholesterol levels. In this touchCARDIO interview, we speak with Prof. Steven Nissen (Cleveland Clinic, Cleveland, OH, USA) to explore current and developing novel lipid-lowering […]
Journal articles and more to your inbox
Get the latest clinical insights from touchCARDIOSign me up!